Publications by authors named "N K Chaudhuri"
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFBackground: Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors.
Aim: To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions.
Methods: A modified international 3-tier Delphi exercise was performed.
Introduction: Nintedanib is approved for the treatment of idiopathic pulmonary fibrosis (IPF), other forms of progressive pulmonary fibrosis (PPF), and systemic sclerosis-associated interstitial lung disease (ILD). We present global post-marketing safety data for nintedanib in these fibrosing ILDs.
Methods: Data on adverse events in patients with fibrosing ILDs who were treated with nintedanib were collected via spontaneous reporting and solicited reporting in various studies (excluding clinical trials).
Article Synopsis
- A study examined demographics and clinical experiences of patients with progressive pulmonary fibrosis (PPF) in five European countries, revealing limited knowledge on their journey and treatment options.
- Data from 1,335 patients indicated a mean onset age of 60.4 years, with a predominant demographic of white, non-smoking females.
- Notable findings included an average delay of nearly 8 months from first symptoms to physician visit and diagnosis, with common symptoms like dyspnoea and cough, and a high rate of prior misdiagnosis, particularly as chronic obstructive pulmonary disease (COPD).
Last minute cancellation of elective lung cancer surgery is associated with poorer survival.
Interdiscip Cardiovasc Thorac Surg
October 2024
Objectives: Our objective was to assess the incidence and reason of last-minute cancellations before surgery for lung cancer and their association with outcomes.
Methods: Retrospective analysis on all consecutive patients booked for elective lung cancer surgery from January 2017 through December 2022 in a single centre.Last minute cancellation: a cancellation occurring within the last 24 hours from the planned operation.